According to our latest study on “Mice Model Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Service, Technology, Indication, End User, Application, and Mode,” the market is expected to grow from US$ 1,705.70 million in 2022 to US$ 2,340.90 million by 2028; it is estimated to grow at a CAGR of 5.4% from 2022 to 2028. The report highlights the key factors driving the market and prominent players with their developments in the market.
Download Sample PDF at https://www.theinsightpartners.com/sample/TIPRE00022453/
North America held the largest share in the mice model market. The growth is attributed to various factors such as the presence of major market players in the region followed by the increase in research & development activities in the US. Moreover, increase in preclinical activities by various pharmaceutical and contract research organizations in the region are further expected to contribute to the growth of the mice model market during the forecast period.
Mice models are essential tools to study the pathogenesis of infectious diseases and for the preclinical evaluation of vaccines and therapies against various human pathogens. The use of genetically defined inbred mouse strains, humanized mice, and gene knockout mice has enabled the research community to study the process of the way pathogens cause diseases, the role of specific host genes in controlling or promoting disease, and potential targets for prevention or identification of treatment for a variety of infectious agents. With the emergence of new infectious diseases, the animal model has become a vital tool for studying disease mechanisms and developing therapeutics. Mice with xenografted human immune systems have been used to study the pathogenesis of various infectious agents, including Plasmodium falciparum (malaria), Mycobacterium tuberculosis, dengue virus, and influenza virus. These models have been beneficial for studying HIV, including analyzing viral and host factors that promote viral replication, HIV interactions with the host’s immune response, and as platforms for testing therapeutic approaches to control or cure HIV infection. Mice models are an essential resource for studying the mechanisms underlying infectious disease pathogenesis and as platforms for testing potential vaccines and therapies. Mice models are necessary for learning about infections from many human pathogens. They are widely used for preclinical screening of vaccines/therapies because of their high reproducibility, low cost, and ease of experimental manipulation.
Over the past century, advances in the development of vaccines, antibiotics/antivirals, and infection control measures have significantly reduced the public health burden of infectious diseases. However, there has been an increase in contagious viral diseases over the years. In the past two decades, there have been three outbreaks of COVID-19—SARS-CoV in 2002, MERS-CoV in 2012, and SARS-CoV-2 in 2019. However, the current SARS-CoV-2 is much more severe than the SARS-CoV in 2002 and has spread to more than 213 countries, affecting millions of people.
Speak to Analyst @ https://www.theinsightpartners.com/speak-to-analyst/TIPRE00022453
The emergence of the COVID-19 pandemic in 2019 has prompted animal models to study its pathology and develop an effective treatment. Aside from coronavirus studies, mice models are considered the best small animal models for hepatitis B virus (HBV), hepatitis C virus (HCV), Zika virus, and cytomegalovirus (CMV). According to the WHO, over 17 million people die from infectious diseases yearly. Over the past two decades, over 30 new infectious diseases have emerged. As per the UNAIDS, 38 million people were affected by HIV at the end of 2019. Mice models have been widely used for various viral studies due to their small size, low cost, ease of use, and high reproducibility. Thus, the growing number of infectious disease is driving the mice model market.
The COVID-19 outbreak has resulted in dramatic reductions in non-urgent medical services. Several countries have imposed lockdowns from 2020 to mid-2021, resulting in delayed hospital visits. Thus, the delayed hospital visits have shown a critical impact on health and postponed the diagnosis of various critical conditions such as cancer and cardiovascular disorders. Hospitals experienced drastic reductions in surgical procedures and annual health checkups to decrease the risk of transmitting SARS-CoV-2 to patients and health care workers within their practice. The lockdown allowed only emergency procedures with stringent preventive measures to avoid spreading SARS-CoV-2. The lockdown has disrupted the supply chain and sales and also led to the closure of production units globally.
The increase in COVID-19 cases has boosted the demand for treatment, thereby increasing the need for mice models and humanized mice models compatible with SARS-CoV-2. This has led to the development of a new mice model based on the requirement, which is likely to support the growth of the mice model market. These models helped the pharmaceutical industry in the development of COVID-19 vaccines and drugs. After the launch of the vaccines in 2021, the pandemic situation was under control. Governments relaxed the restrictions on various services, which further created opportunities for the growth of the mice model market. Thus, the COVID-19 pandemic boosted the growth of the mice model market.
Get a Full Report Copy @ https://www.theinsightpartners.com/buy/TIPRE00022453/
Charles River Laboratories; The Jackson Laboratory; Taconic Biosciences, Inc; TRANS GENIC INC.; GenOway S.A.; Envigo; Janvier Labs; Ozgene Pty Ltd.; Crown Bioscience Inc.; and Harbour BioMed are among the leading companies operating in mice model market.
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Food and Beverages, Consumers and Goods, Chemicals and Materials.
Contact Person : Sameer Joshi .
Phone : +1-646-491-9876
E-mail : email@example.com